Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Liang, Hong ^a,c   Zhang, Jie ^a   Shao, Chen ^b   Zhao, Lijing ^b   Xu, Wei ^a   Sutherland, Leslie C ^d   Wang, Ke ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b Jilin University   (China)

^c Changchun Central Hospital   (China)

^d Northeastern Regional Cancer Centre   (Canada)

Author keywords

Carcinogenesis; EGFR; KRAS; NSCLC; RBM5

Indexed keywords

CELL CYCLE PROTEIN; DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; RAS PROTEIN; RBM5 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84862198466     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-36     Document Type: Article

References (31)

1. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000, 18:106-115.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA: Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003, 163:1949-1960.
4. Hui HP: Population-based differences in treatment outcome following anticancer drug therapies. Lancet 2010, 11:75-84.
5. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
6. Wang L, Xiong Y, Sun Y, Fang Z, Li L, Ji H, Shi T: HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res 2010, 38:665-669.
7. Herbst RS, Heymach JV, Lippman SM: Molecular origins of cancer: lung cancer. N Engl J Med 2008, 359:1367-1380.
8. Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C: Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2010, 10:1-13.
9. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl JMed 2008, 358:1160-1174.
10. Hirsch FR, Varella-Garcia M, Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer Predictive value of EGFR/HER2. Oncogene 2009, 28:32-37.
11. Costa DB, Schumer ST, Tenen DG, Kobayashi S: Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008, 26:1182-1186.
12. Suda K, Tomizawa K, Mitsudomi T: Biological and clinical significance of KRAS mutations in lung cancer: and oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010, 29:49-60.
13. Heidorn SJ, Milagre V, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R: Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell 2010, 1:209-221.
14. Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Canc Genet Cytogenet 2007, 173:107-113.
15. Wei MH, Latif F, Bader S, Kashuba V, Chen JY, Duh FM, Sekido Y, Lee CC, Geil L, Kuzmin I, Zabarovsky E, Klein G, Zbar B, Minna JD, Lerman MI: Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res 1996, 56:1487-1492.
16. Oh JJ, Razfar A, Delgado I, Reed RA, Malkina A, Boctor B, Slamon DJ: 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res 2006, 66:3419-3427.
17. Ji L, Minna JD, Roth JA: 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol 2005, 1(1):79-92.
18. Sutherland LC, Wang K, Robinson AG: RBM5 as a Putative Tumor Suppressor Gene for Lung Cancer. J Thorac Oncol 2010, 5:294.
19. Rintala-Maki ND, Goard CA, Langdon CE, Wall VE, Traulsen KE, Morin CD, Bonin M, Sutherland LC: Expression of RBM5-related factors in primary breast tissue. J Cell Biochem 2007, 100:1440-1458.
20. Edamatsu H, Kaziro Y, Itoh H: LUCA15, a putative tumour suppressor gene encoding an RNA-bindingnuclear protein, is down-regulated in ras-transformed Rat-1 cells. Genes Cells 2000, 5:849-858.
21. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2007, 2(8):706-714.
22. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ: Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005, 11:6333-6341.
23. Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B, Chang LS: cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002, 23:736-748.
24. Oh JJ, West AR, Fishbein MC, Slamon DJ: A candidate tumour suppressor gene, H37, from the human lung cancer tumour suppressor locus 3p21.3. Cancer Res 2002, 62:3207-3213.
25. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecualr signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
26. Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET: Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT transgenic mice: correlation to human disease. Cancer Res 2004, 64:5973-5981.
27. Oh JJ, Taschereau EO, Koegel AK, Ginther CL, Rotow JK, Isfahani KZ, Slamon DJ: RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer 2010, 70:253-262.
28. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
29. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, Yousem SA: Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006, 125:860-865.
30. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr: Varella-Garcia M: Epidermal growth factor receptor gene and protein andgefitinib sensitivity in non-small-cell lung cancer. J Natl Canc Inst 2005, 97:643-655.
31. Sutherland LC, Wang K, Robinson AG: RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol 2010, 5:294-298.